30 Two initial clinical trials conducted in the 1990s that enrolled more than 1500 men and women showed that HSV/AS04 conveyed highly significant protection (73% in one study and 74% in the other study) in a specific population: women (but not men) who were seronegative for HSV-2 and HSV-1. 32 However, a larger Phase III clinical trial in more than 8000 HSV-1 and HSV-2 negative women failed to demonstrate efficacy for reasons that remain unc
1
—
—